Retinopathy Of Prematurity – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Retinopathy Of Prematurity – Drugs In Development, 2024 report and make more profitable business decisions.
Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder, which usually develops in both eyes, is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness. Risk factors for the development of ROP include prematurity, extremely low birth weight, and multiple births.
The Retinopathy Of Prematurity drugs in development market research report provide comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Retinopathy Of Prematurity | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 27 molecules, with 26 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Retinopathy Of Prematurity therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Retinopathy Of Prematurity pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Retinopathy Of Prematurity treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akebia Therapeutics IncANBITION Srl
Anida Pharma Inc
AntlerA Therapeutics Inc
Aspire Pharma Ltd
Ayuvis Research Inc
D. Western Therapeutics Institute Inc
Drive Therapeutics LLC
Elgan Pharma Ltd
Everglades Biopharma LLC
F. Hoffmann-La Roche Ltd
Infant Bacterial Therapeutics AB
Jenivision Inc
Kowa Co Ltd
Novelty Nobility Inc
Oklahoma Medical Research Foundation
Orpheus BioScience LLC
Pamdeca LLC
Recordati Rare Diseases Inc
Regeneron Pharmaceuticals Inc
Shenzhen Evergreen Therapeutics Co Ltd
Signablok Inc
Worphmed Srl
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Retinopathy Of Prematurity reports